학술논문

Circulating acyl-CoA-binding protein/diazepam-binding inhibitor in gestational diabetes mellitus
Document Type
article
Source
Reproductive Biology and Endocrinology, Vol 21, Iss 1, Pp 1-7 (2023)
Subject
Acyl-CoA-binding protein
Adipokines
Diazepam binding inhibitor
Gestational Diabetes Mellitus
Insulin resistance
Pregnancy
Gynecology and obstetrics
RG1-991
Reproduction
QH471-489
Language
English
ISSN
1477-7827
Abstract
Abstract Background Acyl-CoA-binding protein (ACBP)/diazepam-binding inhibitor has recently been characterized as an endocrine factor affecting energy balance and lipid metabolism. However, regulation of ACBP in women with gestational diabetes mellitus (GDM) during pregnancy, as well as postpartum, has not been investigated, so far. Methods ACBP was quantified in 74 women with GDM and 74 healthy, gestational age-matched, pregnant controls using an enzyme-linked immunosorbent assay. Furthermore, ACBP was quantified post-partum in 82 women (i.e. 41 women with previous GDM vs. 41 previous control women). ACBP was related to measures of obesity, hypertension, glucose and lipid metabolism, renal function, and inflammation during pregnancy and postpartum. Results During pregnancy, median [interquartile range] ACBP levels were not significantly different in women with GDM (40.9 [40.0] µg/l) compared to healthy, pregnant controls (29.1 [32.3] µg/l) (p = 0.215). ACBP serum concentrations increased from 30.3 [40.5] µg/l during pregnancy to 59.7 [33.2] µg/l after pregnancy in the entire cohort (p